Quadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction at around Rs 4,500 crore. With ambitions for growth, Samarth Lifesciences is on the lookout for investment, especially after prior negotiations with alternative investors faltered over price evaluations.